Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail shows promise in shrinking breast tumors before surgery

NCT ID NCT00295893

Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two different chemotherapy regimens, with or without the targeted drug trastuzumab, given before surgery to patients with stage II or III breast cancer. The goal was to see which combination better eliminated cancer cells in the breast and lymph nodes. A total of 121 participants received either TAC (docetaxel, adriamycin, cytoxan) or AC followed by Abraxane and carboplatin, with some also getting trastuzumab. The main measure of success was whether no cancer remained after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
combination chemotherapy (docetaxel, doxorubicin, cyclophosphamide, paclitaxel, carboplatin) with or without trastuzumab
What this could lead to
If successful, this could help identify which chemo combination works best before surgery to shrink breast tumors and improve outcomes.
What could go wrong
This is a small, early-phase trial (121 participants) with no long-term results yet. The benefits seen may not apply to all breast cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

121 people

The number who actually took part.

Started

Sep 2005

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically proven infiltrating ductal or lobular breast carcinoma * Stage II or III disease * Inflammatory breast cancer allowed * Hormone-receptor status not specified PATIENT CHARACTERISTICS: * ECOG performance status \< 2 * Male or female * Menopausal status not specified (for female patients) * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Bilirubin normal (except for patient's with Gilbert's disease) * Creatinine ≤ 1.2 mg/dL * Creatinine clearance ≥ 70 mL/min * Ejection fraction ≥ 50% on MUGA * No neuropathy ≥ grade 1 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective nonhormonal contraception * No prior malignant disease within the past 5 years, excluding: * Squamous cell or basal cell skin carcinoma * Stage I or in situ cervical carcinoma * No noninvasive (in situ) breast carcinoma within the past 5 years PRIOR CONCURRENT THERAPY: * At least 5 years since prior antiestrogen treatment for any indication other than breast cancer prevention (tamoxifen, raloxifene, or an aromatase inhibitor) * No prior radiotherapy to the chest wall

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast ductal adenocarcinoma breast neoplasm Carcinoma, Lobular inflammatory breast carcinoma male breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010-3000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.